Amiloride selectively inhibits the urokinase-type plasminogen activator

FEBS Lett. 1987 Apr 6;214(1):187-91. doi: 10.1016/0014-5793(87)80039-x.

Abstract

The diuretic drug amiloride, an inhibitor of Na+ uptake, competitively inhibits the catalytic activity of the urokinase-type plasminogen activator (u-PA), with a Ki of 7 X 10(-6) M. Generation of plasmin, cleavage of peptide substrates, and interaction of u-PA with a specific macromolecular proteinase inhibitor are all prevented in the presence of the drug. In contrast, amiloride does not affect the activity of either tissue-type plasminogen activator, plasmin, plasma kallikrein or thrombin. The inhibition of u-PA by amiloride may be related to the previously reported inhibition of u-PA-type enzymes by Na+. Amiloride or related compounds could prove useful in selectively controlling u-PA-catalyzed extracellular proteolysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amiloride / pharmacology*
  • Animals
  • Humans
  • In Vitro Techniques
  • Kinetics
  • Plasminogen Activators / antagonists & inhibitors*
  • Plasminogen Inactivators*
  • Protease Inhibitors / metabolism
  • Sodium / metabolism
  • Tissue Plasminogen Activator / antagonists & inhibitors
  • Urokinase-Type Plasminogen Activator / antagonists & inhibitors*

Substances

  • Plasminogen Inactivators
  • Protease Inhibitors
  • Amiloride
  • Sodium
  • Plasminogen Activators
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator